THE EVALUATION OF DRUG INTERACTIONS IN PRESCRIPTIONS FOR HEART DISEASE PATIENTS AT THE XYZ PHARMACY IN 2024

DRUG INTERACTIONS
Miftahul Hidayati 1 Indonesia ROR , Rahmadevi 2 Indonesia
1 Universitas Adiwangsa Jambi ROR
2 Universitas Adiwangsa
Link Copied!
Published 2026-06-20
Vol. 8 No. 1 (2026) PAGES 195-203
DOI 10.36566/ijhsrd/Vol8.Iss1/384
Views / Downloads 114 79

Background: Cardiovascular disease is a major cause of morbidity and mortality, with treatment commonly involving polypharmacy, which increases the risk of drug interactions.

Methods: This study aimed to evaluate potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. This study used a descriptive observational design with a retrospective approach through prescription review. A total of 45 prescriptions that met the inclusion criteria were selected using total sampling. Data were analyzed descriptively using frequency and percentage.

Results: The results showed that most prescriptions contained 3–4 drugs (62.2%), indicating polypharmacy. A total of 92 potential drug interaction cases were identified, consisting of 79.30% pharmacodynamic interactions and 20.70% pharmacokinetic interactions. Pharmacokinetic interactions occurred during the absorption, distribution, metabolism, and excretion phases, with examples including digoxin–spironolactone, clopidogrel–lansoprazole, and metformin–furosemide. The most common interaction combinations occurred between cardiovascular drugs (54.35%).

Conclusion: In conclusion, there are potential pharmacokinetic drug interactions in prescriptions of heart disease patients at XYZ Pharmacy in 2024. These findings highlight the importance of drug interaction screening in pharmaceutical services to improve the safety and effectiveness of therapy.

THE EVALUATION OF DRUG INTERACTIONS IN PRESCRIPTIONS FOR HEART DISEASE PATIENTS AT THE XYZ PHARMACY IN 2024: DRUG INTERACTIONS. (2026). INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD), 8(1), 195-203. https://doi.org/10.36566/ijhsrd/Vol8.Iss1/384
Download data is not yet available.
  1. 1. Aljadhey, H., et al. (2016). Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care, 28(4), 450–455.
  2. 2. Aronson, J. K. (2016). Meyler’s side effects of drugs: The international encyclopedia of adverse drug reactions and interactions (16th ed.). Elsevier.
  3. 3. Ayuningsih, I. (2022). Potensi kejadian interaksi obat pada pasien penyakit jantung koroner rawat jalan di RSKD Duren Sawit. Repository Poltekkes Kemenkes Jakarta II.
  4. 4. Badan Penelitian dan Pengembangan Kesehatan. (2018). Laporan Nasional Riskesdas 2018.
  5. 5. Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019). Heart disease and stroke statistics—2019 update: A report from the American Heart Association. Circulation, 139(10), e56–e528.
  6. 6. Crawford, C., Patel, J., & Hockings, L. (2019). Role of P-glycoprotein in cardiovascular drug interactions. Journal of Clinical Pharmacology, 59(9), 1175–1187.
  7. 7. Fajariyani, A., Mariyana, T., & Rachmawati, P. (2024). Kajian retrospektif potensi interaksi obat resep polifarmasi pada pasien poli jantung di Rumah Sakit X di Karawang. The Journal General Health and Pharmaceutical Sciences Research, 2(2), 08–16.
  8. 8. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., & Williams, K. M. (2016). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 55(1), 81–98.
  9. 9. Gurbel, P. A., & Tantry, U. S. (2014). Antiplatelet therapy and bleeding risk. Circulation, 129(25), 2686–2698.
  10. 10. Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2014). Predicting and manipulating cardiac drug inactivation by Eggerthella lenta. Science, 341(6143), 295–298.
  11. 11. Hilmer, S.N. & Gnjidic, D. (2018). The effects of polypharmacy in older adults. Clin Pharmacol Ther, 103(2), 186–188.
  12. 12. Islamiyah, A.N. (2021). Telaah Potensi Interaksi Obat Resep Polifarmasi Klinik Jantung pada Salah Satu Rumah Sakit di Bandung. Kartika: Jurnal Ilmiah Farmasi, 8(1), 25-35.
  13. 13. Kim, J., Lee, H., & Park, S. (2024). Impact of proton pump inhibitors on clopidogrel responsiveness and clinical outcomes: A systematic review. Biomedicines, 12(1), 115–128.
  14. 14. Li, X., Andersson, T. B., Ahlström, M., & Weidolf, L. (2021). Comparison of inhibitory effects of proton pump-inhibiting drugs on human cytochrome P450 activities. Frontiers in Pharmacology, 12, 694371.
  15. 15. Mangoni, A.A. & Jackson, S.H.D. (2017). Age-related pharmacokinetic and pharmacodynamic changes: basic principles and clinical relevance. Br J Clin Pharmacol, 83(6), 1036–1046.
  16. 16. Mengistie, Y. G., Bitew, H. B., Tuha, A., & Hailu, H. G. (2021).
  17. Assessment of Potential Drug–Drug Interactions and Their Predictors in Chronic Outpatient Department of Dessie Referral Hospital, Northeast Ethiopia. Drug, Healthcare and Patient Safety, 13, 29–35.
  18. 17. Midão, L., Giardini, A., Menditto, E., Kardas, P., & Costa, E. (2018). Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Archives of Gerontology and Geriatrics, 78, 213–220.
  19. 18. Mullish, B. H., Williams, H. R. T., & Marchesi, J. R. (2018). The gut microbiome and pharmacology. Clinical Medicine, 18(3), 224–227.
  20. 19. Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016). Drugs that may cause or exacerbate heart failure. Circulation, 134(6), e32–e69.
  21. 20. Palmer, B. F., & Clegg, D. J. (2019). Diuretics and potassium balance. The New England Journal of Medicine, 381(1), 60–72.
  22. 21. Radu, A.-F., Radu, A., Bungau, G. S., Tit, D. M., Vesa, C. M., Jurca, T., Uivarosan, D., Gitea, D., Brata, R., & Bustea, C. (2026). Polypharmacy and drug–drug interaction architecture in hospitalized cardiovascular patients: Insights from real-world analysis. Biomedicines, 14(1), 218.
  23. 22. Shi, S., Morike, K., & Klotz, U. (2020). The clinical implications of ageing for rational drug therapy. European Journal of Clinical Pharmacology, 76, 107–115.
  24. 23. Spanakis, M., Alexakis, K., & Ioannou, P. (2025). Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review. Frontiers in Pharmacology, 16, 1685710.
  25. 24. Stopfer, P., Giessmann, T., Hohl, K., Sharma, A., Ishiguro, N., Taub, M. E., Zimdahl-Gelling, H., Gansser, D., Wein, M., Ebner, T., & Mueller, F. (2016). Pharmacokinetic interaction between the MATE1 transporter inhibitor and metformin. Clinical Pharmacology & Therapeutics, 100(5), 482–492.
  26. 25. Suharyani, S. (2015). Evaluasi penggunaan kombinasi obat digoksin dan furosemid pada pasien gagal jantung. Jurnal Kesehatan, 6(2), 701–708.
  27. 26. Wedemeyer, R. S., & Blume, H. (2014). Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety, 37(4), 201–211.
  28. 27. Weir, M. R., & Rolfe, M. (2010). Potassium homeostasis and renin–angiotensin–aldosterone system inhibitors. Clinical Journal of the American Society of Nephrology, 5(3), 531–548.
  29. 28. World Health Organization. (2023). Cardiovascular diseases (CVDs).

Copyright (c) 2026 INDONESIAN JOURNAL OF HEALTH SCIENCES RESEARCH AND DEVELOPMENT (IJHSRD)

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright Rights & Permissions Guide

Reproducing Published Material from other Publishers

It is absolutely essential that authors obtain permission to reproduce any published material (figures, schemes, tables or any extract of a text) which does not fall into the public domain, or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).

Permission is required for:

  1. Your own works published by other Publishers and for which you did not retain copyright.
  2. Substantial extracts from anyones’ works or a series of works.
  3. Use of Tables, Graphs, Charts, Schemes and Artworks if they are unaltered or slightly modified.
  4. Photographs for which you do not hold copyright.

Permission is not required for:

  1. Reconstruction of your own table with data already published elsewhere. Please notice that in this case you must cite the source of the data in the form of either “Data from…” or “Adapted from…”.
  2. Reasonably short quotes are considered fair use and therefore do not require permission.
  3. Graphs, Charts, Schemes and Artworks that are completely redrawn by the authors and significantly changed beyond recognition do not require permission.

Obtaining Permission

In order to avoid unnecessary delays in the publication process, you should start obtaining permissions as early as possible. If in any doubt about the copyright, apply for permission. JNH cannot publish material from other publications without permission.

The copyright holder may give you instructions on the form of acknowledgement to be followed; otherwise follow the style: “Reproduced with permission from [author], [book/journal title]; published by [publisher], [year].’ at the end of the caption of the Table, Figure or Scheme.

Every mansucript should be accompanied by "Copyright Transfer Agreement" prior to the article publication

Dimension Badge

Downloads

Downloads
Crossmark Badge
Crossmark Badge
Section
Articles
Keywords
Pharmacokinetics Drug interaction Polypharmacy

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)